Ascendis制药

ASND NASDAQ
128.00
+7.11
+5.88%
已收盘, 16:55 06/17 EDT
开盘
121.02
昨收
120.89
最高
128.45
最低
120.98
成交量
32.92万
成交均量(3M)
29.06万
52周最高
133.96
52周最低
53.21
换手率
0.70%
市值
60.07亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Ascendis制药 ASND股票价格,Ascendis制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
展开 >

最近浏览

名称
价格
涨跌幅